Safety of oral bisphosphonates: Controlled studies on alveolar bone

Oral Bisphosphonate-Induced Osteonecrosis: Risk Factors, Prediction of Risk Using Serum CTX Testing, Prevention, and Treatment

“…38,39 Dental implant placements are also likely safe and will osseointegrate during this period. 40 However, informed consent should be provided as to an increased risk for implant failure or osteonecrosis about the implants once the oral bisphosphonate exposure exceeds 3 years.…”

Dental implants in patients treated with oral Bisphosphonates: A bibliographic review

“…Of the sixty-one patients treated with 169 implants by Fugazzotto et al (12) with an average bisphosphonate medication period of 3.3 years, there was one case of bone exposure of the torus around a post-extraction implant, which closed spontaneously after four weeks. Jeffcoat (13) found that, of 102 implants in patients taking bisphosphonates over periods ranging between one and four years (average 3±0.1 years) before surgery, not a single implant was lost. There was no occurrence of osteonecrosis and no significant differences were found when results were compared with a control group who did not take the drug.…”

Management of atrophic maxilla in severe osteoporosis treated with bisphosphonates: a case report

“…42 Little is known of the risks associated with long-term use of oral BPs despite their use for more than 10 years as an oral mode of delivery for the treatment of osteopenia, osteoporosis, and Paget disease of bone. Some authors reported in a controlled study that problems with implants in patients taking oral BPs are relatively rare.. 27 Furthermore, BPs demonstrate the potential to oversuppress bone turnover rates and inhibit angiogenesis, thus impairing the reparative properties of bone, 42,44,45 which is why the angiogenic properties of PRP could be beneficial for bone healing in such patients. 46,47 Recently Fugazzotto et al reported that after a mean period of 3.3 years (range 1-5 years) of oral BP use, no correlation was found with the development of osteonecrosis after implant placement.. 48 Cartsos et al claimed that the mode of BP use results in different risk profiles for developing ONJ.…”

“…Although ONJ has been associated with the prolonged use of BPs, there is limited information about the risk of ONJ among users of oral BPs or about the magnitude of the risk among users of intravenous BPs. [25][26][27] Recently the potential benefits of using platelet-rich plasma (PRP) in optimal osseous wound repair have been reported. 28,29 Platelet-rich plasma is a fibrin adhesive with a higher platelet concentration, easily obtained from whole blood centrifugation, and contains angiogenic and mitogenic growth factors derived from the platelets' alpha granules.…”